Publication | Open Access

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Advanced Cervical CancerCervical Cancer ManagementCervical CancerCervical HealthMedicineMetronomic TherapyAdverse Event AnalysisGynecologyFinal Overall SurvivalCancer TreatmentOncologyRadiation OncologyGynecology OncologyHealth Sciences